References
- Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796–806.
- Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis 1970; 101:780–2.
- Weber WW, Hein DW. Clinical pharmacokinetics of isoni-azid. Clin Pharmacokinet 1979;4:401–22.
- Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, . Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997;155:1717–22.
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–62.
- World Health Organization. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. Available at: //www.who.int/entity/tb/challenges/interim_paediatric_fdc_dosing_instructions_sept09.pdf(accessed December 2009).
- Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536–48.
- Advenier C, Saint-Aubin A, Scheinmann P, Paupe J. [The pharmacokinetics of isoniazid in children] (author's translation). Rev Fr Mal Respir 1981;9:365–74.
- Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP. Cerebrospinal fluid isoniazid concentrations in children 5 with tuberculous meningitis: the influence of dosage and acetylation status. Paediatrics 1992;89:247–50.
- McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, . Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international paediatric dosing guidelines. Clin Infect Dis 2009;48:1547–53.
- Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, . Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005;90:614–8.
- Bartmann K, Massmann W. [The blood level of isoniazid in adults and children]. Beitr Klin Tuberk Spezif Tuberkulose-forsch 1960;122:239–50.
- Bartmann K, Massmann W. [Experimental studies on dosage of isoniazid]. Beitr Klin Tuberk Spezif Tuberkuloseforsch 1961;124:310–9.
- Bartmann K, Massmann W. [On the Schmiedel method of microbiological isoniazid determination]. Beitr Klin Tuberk Spezif Tuberkuloseforsch 1960;122:192–7.
- Olson WA, Pruitt AW, Dayton PG. Plasma concentrations of isoniazid in children with tuberculous infections. Paediatrics 1981;67:876–8.
- Chumlea WC, Guo SS, Zeller CM, Reo NV, Siervogel RM. Total body water data for white adults 18 to 64 years of age: the Fels Longitudinal Study. Kidney Int 1999;56:244–52.
- Fomon SJ, Haschke F, Ziegler EE, Nelson SE. Body composition of reference children from birth to age 10 years. Am J Clin Nutr 1982;35(5 Suppl):1169–75.
- Hume R, Weyers E. Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol 1971;24:234–8.
- Otto H, Magdorf K. Aktueller Stand der antituberkulösen Chemotherapie im Kindesalter. Prax Klin Pneumol 1981;35:588–95.
- Thee S, Detjen A, Quarcoo D, Wahn U, Magdorf K. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int J Tuberc Lung Dis 2007;11:965–71.
- Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Phar-macokinet 2008;47:231–43.
- Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, . The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997;156:895–900.
- Peloquin CA. Therapeutic drug monitoring: principles and application in mycobacterial infections. Drug Ther 1992;22:31–6.
- Peloquin CA. Antituberculosis drugs: pharmacokinetics. Heifets LB. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991 59–88.
- Heifets LB. Drug susceptibility tests in the management of chemotherapy of tuberculosis. Heifets LB. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. 89–122.
- Hearn MJ, Cynamon MH. In vitro and in vivo activities of acylated derivatives of isoniazid against Mycobacterium tuberculosis. Drug Des Discov 2003;18:103–8.
- Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, . The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004;39:1425–30.